^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    atorvastatin

    i
    Other names: YM 548, CI 981
    Company:
    Generic mfg.
    Drug class:
    HMG-CoA reductase inhibitor
    Related drugs:
    6d
    A Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    atorvastatin
    7d
    Statins Study in Children of Acute Kawasaki Disease With Coronary Artery Abnormalities (clinicaltrials.gov)
    P=N/A, N=9, Not yet recruiting, Children's Hospital of Fudan University
    New trial
    |
    atorvastatin
    7d
    A Clinical Study of Ulonivirine (MK-8507) With Atorvastatin and Metformin in Healthy Adults (MK-8507-018) (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1 trial
    |
    atorvastatin
    8d
    V-ACCELERATE: Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction (clinicaltrials.gov)
    P4, N=334, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    APOB (Apolipoprotein B)
    |
    atorvastatin
    9d
    A Pathogenic ROCK-Signaling Network Involving a Lysine Deletion in Myh11 Renders Carriers Susceptible to Aortic Dissection. (PubMed, Int J Mol Sci)
    Furthermore, it predicted 51 candidate therapeutants, including atorvastatin, GSK-269962A, and atovaquone. These findings indicate that even in the absence of overt pathological stimulation, aortic tissue carrying the Myh11 K1256del variant exhibits a transcriptional program centered on ROCK signaling, which may prime the aorta for maladaptive responses to additional stress and may enhance susceptibility to dissection. This computational analysis requires experimental validation, but may provide a hypothesis-generating framework for development of preventive pharmacological interventions against FTAAD.
    Journal
    |
    NFATC1 (Nuclear Factor Of Activated T Cells 1) • JUNB (JunB Proto-Oncogene AP-1 Transcription Factor Subunit)
    |
    atorvastatin • atovaquone
    10d
    SATURN: Use of statins in patients with intracerebral hemorrhage (2024-511465-11-00)
    P2/3, N=180, Recruiting, Fundacio Institut De Recerca De L Hospital De La Santa Creu I Sant Pau | Not yet recruiting --> Recruiting
    Enrollment open
    |
    simvastatin • atorvastatin
    19d
    Atorvastatin-Driven Methuosis in Glioblastoma: A Biomimetic Nanodrug for Targeted Tumor Therapy. (PubMed, ACS Nano)
    In vitro experiments confirmed the cytotoxicity and induction of methuosis in GBM cells by AP@CM-Ang, accompanied by the release of immune-stimulatory factors. In vivo experiments demonstrated that the nanodrug significantly enhanced tumor targeting, effectively inhibited tumor growth, and increased immune cell activation, validating its potential as a promising and safe strategy for GBM treatment.
    Journal
    |
    PD-1 (Programmed cell death 1)
    |
    atorvastatin
    23d
    Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    |
    atorvastatin
    26d
    Atorvastatin Therapy on Xanthoma in Alagille Syndrome (clinicaltrials.gov)
    P4, N=15, Completed, Children's Hospital of Fudan University | Recruiting --> Completed | N=10 --> 15
    Trial completion • Enrollment change
    |
    atorvastatin
    28d
    CHORMONE: The relationship of cholesterol-lowering drugs with steroid HORMONEs, bile acids, muscle morphology, vitamin D, the immune system and related diseases such as depression and osteoporosis (2024-516967-10-00)
    P4, N=250, Recruiting, Medical University Of Vienna | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Repatha (evolocumab) • atorvastatin • Praluent (alirocumab)
    1m
    CKJX839A12309: Evaluation of efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes (2025-521670-34-00)
    P2/3, N=135, Not yet recruiting, Novartis Pharma AG | N=24 --> 135
    Enrollment change
    |
    atorvastatin